Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacyclics LLC.
With
Janssen Research & Development, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligibility Criteria for the Randomized Study
Untreated or previously treated for WM. Previously treated subjects must have either documented disease progression or had no response (stable disease) to the most recent treatment regimen
Centrally confirmed clinicopathological diagnosis of WM
Measurable disease defined as serum monoclonal immunoglobulin M (IgM) \>0.5 g/dL
Symptomatic disease meeting at least 1 of the recommendations from the Second International Workshop on Waldenström Macroglobulinemia for requiring treatment
Hematology and biochemical values within protocol-defined limits
Men and women ≥ 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
You may not be if
Known involvement of the central nervous system by WM
Disease that is refractory to the last prior rituximab-containing therapy defined as either
* Relapse after the last rituximab-containing therapy \< 12 months since last dose of rituximab, OR
* Failure to achieve at least a minor response (MR) after the last rituximab-containing therapy If the subject meets this exclusion criterion and therefore is excluded from the main randomized study, participation in the non randomized substudy (Arm C) may be considered
Rituximab treatment within the last 12 months before the first dose of study drug
Known anaphylaxis or (immunoglobulin E) IgE-mediated hypersensitivity to murine proteins or to any component of rituximab
Prior exposure to ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitors
Known bleeding disorders (eg, von Willebrand's disease) or hemophilia
History of stroke or intracranial hemorrhage within 12 months prior to enrollment.
Any uncontrolled active systemic infection.
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
Currently active, clinically significant cardiovascular disease
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Eligibility Criteria for Open-label Substudy Treatment Arm C
Relapse after the last rituximab-containing therapy \<12 months since last dose of rituximab, OR
Failure to achieve at least a MR after the last rituximab-containing therapy.
Clareo Health | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
